BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20384522)

  • 1. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
    Durrant LG; Pudney V; Spendlove I; Metheringham RL
    Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL5 as an adjuvant for cancer immunotherapy.
    Lapteva N; Huang XF
    Expert Opin Biol Ther; 2010 May; 10(5):725-33. PubMed ID: 20233026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of T-cell inhibition: implications for cancer immunotherapy.
    Mittendorf EA; Sharma P
    Expert Rev Vaccines; 2010 Jan; 9(1):89-105. PubMed ID: 20021308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells as therapeutic vaccines against cancer.
    Banchereau J; Palucka AK
    Nat Rev Immunol; 2005 Apr; 5(4):296-306. PubMed ID: 15803149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines.
    Gross S; Geldmacher A; Sharav T; Losch F; Walden P
    Vaccine; 2009 May; 27(25-26):3398-400. PubMed ID: 19200836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic cancer vaccines.
    Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
    Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccination.
    Del Vecchio M; Parmiani G
    Forum (Genova); 1999; 9(3):239-56. PubMed ID: 10504171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines: preclinical studies and novel strategies.
    Palena C; Abrams SI; Schlom J; Hodge JW
    Adv Cancer Res; 2006; 95():115-45. PubMed ID: 16860657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of cancer].
    Andersen MH; Schmidt H; Gehl J; von der Maase H; Straten P
    Ugeskr Laeger; 2002 Jun; 164(23):3008-16. PubMed ID: 12082849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taming cancer by inducing immunity via dendritic cells.
    Palucka AK; Ueno H; Fay JW; Banchereau J
    Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccination against human papilloma virus induced malignancies.
    van der Burg SH; Melief CJ
    Curr Opin Immunol; 2011 Apr; 23(2):252-7. PubMed ID: 21237632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.